Prima BioMed (NASDAQ:IMMP) Now Covered by Analysts at Citizens Jmp

Citizens Jmp assumed coverage on shares of Prima BioMed (NASDAQ:IMMP) in a research note issued to investors on Monday morning,Benzinga reports. The brokerage issued a market outperform rating and a $10.00 target price on the biotechnology company’s stock.

Other equities analysts have also recently issued reports about the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Prima BioMed in a research note on Monday, December 29th. Wall Street Zen upgraded shares of Prima BioMed from a “sell” rating to a “hold” rating in a research report on Saturday, February 14th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $10.00.

Prima BioMed Trading Up 3.2%

Shares of IMMP stock opened at $2.88 on Monday. Prima BioMed has a 12 month low of $1.32 and a 12 month high of $3.53. The stock has a 50 day moving average of $2.88 and a 200-day moving average of $2.21.

Institutional Investors Weigh In On Prima BioMed

An institutional investor recently raised its position in Prima BioMed stock. Jane Street Group LLC lifted its stake in Prima BioMed Ltd (NASDAQ:IMMP) by 14.7% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 51,574 shares of the biotechnology company’s stock after buying an additional 6,617 shares during the period. Jane Street Group LLC’s holdings in Prima BioMed were worth $91,000 at the end of the most recent reporting period. Institutional investors own 2.32% of the company’s stock.

Prima BioMed Company Profile

Prima BioMed, trading as IMMP on NASDAQ, is a clinical-stage biotechnology company specializing in the development of immunotherapy products for cancer treatment. The company’s core technology platform centers on targeting the lymphocyte activation gene-3 (LAG-3), a checkpoint receptor that modulates T-cell activity. Prima BioMed’s lead candidate, eftilagimod alpha (IMP321), is a soluble LAG-3 protein designed to enhance antigen-presenting cell function and stimulate a tumor-specific immune response.